We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bioinformatics Tool for Evaluating the Evaluation of Cancer Genes

By LabMedica International staff writers
Posted on 28 Dec 2016
Researchers offer a new software tool being developed to help assess computational algorithms used in methods to identify mutant genes that drive cancer. More...
The tool could thereby lead to more precise diagnostics and targeted treatments for patients.

In the search for new ways to tackle cancer, many scientists use genome sequencing to hunt for mutations that facilitate tumor cell growth. To aid in this search, some researchers have developed new bioinformatics methods that each claim to help pinpoint the cancer driver mutants. But a question remains: Among the numerous new tactics, which produce more accurate results?

To help solve this puzzle, a team of Johns Hopkins University (Baltimore, MD, USA) computational scientists and cancer experts devised the new tool to help assess how well current strategies work in identifying cancer-promoting mutations and distinguishing them from benign mutations in cancer cells.

"Identifying the genes that cause cancer when altered is often challenging, but is critical for directing research along the most fruitful course," said co-author Bert Vogelstein, Johns Hopkins Kimmel Cancer Center, "This paper establishes novel ways to judge the techniques used to identify true cancer-causing genes and should considerably facilitate advances in this field in the future."

Lead author Collin J. Tokheim, doctoral student in the laboratory of senior author Rachel Karchin, associate professor at Johns Hopkins, said one of the challenges the team faced was the lack of a widely accepted consensus on what qualifies as a cancer driver gene. "People have lists of what they consider to be cancer driver genes, but there's no official reference guide, no gold standard," said Tokheim. Nevertheless, the team was able to develop a machine-learning-based method for driver gene prediction and a framework for evaluating and comparing other prediction methods.

For the study, this evaluation tool was applied to 8 existing cancer driver gene prediction methods. The results were not very reassuring. “These methods still need to get better. We're sharing our methodology publicly, and it should help others to improve their systems for identifying cancer driver genes," said Tokheim.

The study, by Tokheim CJ et al, was published December 13, 2016, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Johns Hopkins University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Pathology

view channel
Image: Virtual staining of label-free tissue in imaging mass spectrometry (Photo courtesy of Ozcan Lab/UCLA)

Deep Learning Advances Imaging Mass Spectrometry with Virtual Histological Detail

Imaging mass spectrometry (IMS) is a powerful technique that can map thousands of molecular species in biological tissues with exceptional chemical specificity. However, IMS is hindered by relatively low... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.